Pliant Therapeutics, Inc. (NASDAQ:PLRX) Analysts Recommend 'Buy'

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has received a consensus recommendation of "Buy" from analysts who cover the stock. According to recent reports, nine brokerage firms have provided ratings on the company, with a majority showing positive sentiment.

Among the nine analysts, eight have issued a buy rating while one analyst has given a strong buy recommendation for Pliant Therapeutics. This indicates a strong level of confidence in the stock's future performance.

Current Stock Price and Market Predictions

The current stock price of Pliant Therapeutics is $14.52, marking an increase of 3.20%. Analysts have set the average price target for the stock at $40.57, suggesting a potential upside of approximately 179.42% from the current market price.

The highest price target assigned by analysts is $45.00, while the lowest price target stands at $33.00. This range underscores analysts' bullish outlook on the stock's growth over the next year.

Analyst Consensus and Ratings Over Time

The consensus rating for Pliant Therapeutics is determined through a systematic evaluation of reports from Wall Street analysts. Each analyst provides a rating that is normalized to a standardized score, helping to create a clearer picture of the stock's performance. A score above 3.0 indicates a buy recommendation, which is the case for PLRX.

The following summary outlines the consensus ratings by month, highlighting changing sentiments among analysts. Over time, these ratings will help investors understand the evolving view on Pliant Therapeutics.

Pliant Therapeutics Compared to Competitors

When compared to similar companies, Pliant Therapeutics boasts a consensus rating score of 3.11, which is higher than the average 2.79 for medical companies and significantly above the 2.50 for the S&P 500. This positions Pliant in a favorable light regarding analyst sentiment.

Furthermore, the predicted upside for PLRX is notably higher than its competitors, showcasing the strong belief in its growth potential. Currently, news sentiment regarding Pliant is neutral, but as developments unfold, perceptions may shift.

Recent Analyst Actions and Recommendations

Several analysts have updated their predictions and ratings for Pliant Therapeutics in the past months. Key actions include:

• On 9/13/2024, HC Wainwright reiterated a buy rating with a price target of $38.00
• On 9/9/2024, Leerink Partners upgraded their rating to strong buy
• Various adjustments have also been made to price targets, reflecting the dynamic nature of the market and analysts' ongoing evaluations.

This continuous flow of new ratings and updates from analysts indicates a robust engagement with the stock, further supporting its potential in the market.

Overall, the current consensus from analysts suggests that Pliant Therapeutics is an attractive investment, particularly for those looking to capitalize on anticipated growth in the biotech sector.

Pliant, Therapeutics, Buy